Abstract Somatic mutations in the IDH1 gene encoding cytosolic NADP?-dependent isocitrate dehydrogenase have been shown in the majority of astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO grades II and III. IDH2 encoding mitochondrial NADP?-dependent isocitrate dehydrogenase is also mutated in these tumors, albeit at much lower frequencies. Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors. To determine mutation types and their frequencies, we examined 1,010 diffuse gliomas. We detected 716 IDH1 mutations and 31 IDH2 mutations. We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III. We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor entities. IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors. In addition, patients with anaplastic glioma harboring IDH1 mutations were on average 6 years younger than those without these alterations.
Introduction
Extraordinary high rates of spontaneous mutations in the gene encoding cytosolic NADP?-dependent isocitrate dehydrogenase (IDH1) have been reported in diffuse gliomas of World Health Organization (WHO) grades II and III of astrocytic and oligodendroglial lineages [1, 8, 17, 21] and in lower frequency mutations in the gene encoding mitochondrial NADP?-dependent isocitrate dehydrogenase (IDH2) [21] . In contrast, mutations of IDH1 are rare in primary glioblastoma [1, 2, 8, 9, 14, 17, 21] . These mutations appear to be of significant importance for survival of patients. Patients with anaplastic astrocytoma and glioblastoma show significantly longer overall survival in the presence of IDH1 or IDH2 mutations [21] . The analysis of a prospective study demonstrated that the absence of IDH1 mutations in anaplastic astrocytoma, oligoastrocytoma and oligodendroglioma of WHO grade III is a strong indicator for poor prognosis [20] .
Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to a-ketoglutarate.
Five genes encoding human isocitrate dehydrogenases have been identified. IDH1 on 2q33.3 encodes cytosolic NADP?-specific isocitrate dehydrogenase [13] . IDH1 is configured as a homodimer with two enzymatically active sites and most of its activity is detected in the cytosol and in peroxisomes [4] . A major function of IDH1 is believed to be the synthesis of NADPH required for reducing reactions and for lipid synthesis [16] . IDH2 on 15q26.1 encodes the mitochondrial NADP?-specific isocitrate dehydrogenase [5] . Similar to IDH1, this enzyme functions as a homodimer. Recent findings suggest that the IDH2 may be the main catalyst for the oxidation of isocitrate to a-ketoglutarate in the citric acid cycle [6] . IDH3 is composed of three subunits encoded by IDH3A (subunit alpha) on 15q25.1-q25.2 [7] , by IDH3B (subunit beta) on 20p13 [10] and by IDH3G (subunit gamma) on Xq28. IDH3 is a multi-tetrameric enzyme (2a1b1c) with a-subunits being catalytic and the b-and c-subunits being believed to be regulatory [15, 19] . IDH3 utilizes NAD? as a coenzyme. The function of IDH3 in the citric acid cycle is well established.
Glioma-specific mutations in IDH1 always affected the amino acid arginine in position 132 of the amino acid sequence which belongs to an evolutionary highly conserved region located at the binding site for isocitrate [14] . Mutations in IDH2 were exclusively detected in arginine at position 172 which is the analogous site to arginine 132 in IDH1 [21] . Mutations in both IDH1 and IDH2 are heterozygous and of somatic origin. The role of IDH1 mutations in tumor biology currently is intensely studied. Mutations inactivate enzyme activity [21] . This inactivation is due to impaired substrate affinity, and moreover, IDH1 mutations exert a dominant negative effect rendering heterodimers inactive as well [22] . Enzyme deficiency results in depletion of a-ketoglutarate which is required for prolylhydroxylases promoting degradation of hypoxia inducible factor 1a (HIF-1a). Increased HIF-1a levels in gliomas carrying the IDH1 R132H mutations have been demonstrated [22] . However, there are many other oxygenases which are dependent on a-ketoglutarate and which are involved in different processes such as histone modification or fatty acid metabolism [11] . Therefore, several other tumor relevant mechanisms besides HIF-1a stabilization may result from IDH1 mutation-mediated depletion of a-ketoglutarate.
In order to determine the different types of mutations and their frequencies, we examined 1,010 human gliomas for mutations in codons 132 and 172 in the genes for IDH1 and IDH2, respectively. Because high frequencies of IDH1 mutations have been described only in few glioma subtypes, we focussed on these entities including WHO grades II and III astrocytomas, oligodendrogliomas and oligoastrocytomas in the present study.
Materials and methods
Tumor specimens average patient age and sex ratio DNA samples from human brain tumors diagnosed at the Departments of Neuropathology of the Universities of Heidelberg, Bonn, Düsseldorf, Nijmegen, Magdeburg and at the Charité Berlin were analyzed. All tumors were diagnosed and classified according to the WHO classification of tumors of the nervous system [12] . The series consisted of 1,010 diffuse gliomas including 227 diffuse astrocytomas WHO grade II (A II), 228 anaplastic astrocytomas WHO grade III (A III), 128 oligodendrogliomas WHO grade II (O II), 174 anaplastic oligodendrogliomas WHO grade III (O III), 76 oligoastrocytomas WHO grade II (OA II) and 177 anaplastic oligoastrocytomas (OA III). The IDH1 mutation data of 281 patients in this series have been reported in a preceding study [1] . The mean ages and female to male sex ratios were 37 years and 44-56% for A II, 42 years and 40-60% for A III, 44 years and 43-57% for O II, 49 years and 47-53% for O III, 43 years and 62-38% for OA II and 47 years and 45-55% for OA III.
PCR amplification
Primer design was based on accession numbers NM_005896 for IDH1 and NM_002168 for IDH2 (http:// www.ncbi.nlm.nih.gov). A fragment of 129 bp length spanning the sequence encoding the catalytic domain of IDH1 including codon 132 was amplified using 60 ng each of the sense primer IDH1f CGGTCTTCAGAGAAGCC ATT and the antisense primer IDH1r GCAAAATCACAT TATTGCCAAC. PCR using standard buffer conditions, 20 ng of DNA and GoTaq DNA Polymerase (Promega, Madison, WI, USA) employed 35 cycles with denaturing at 95°C for 30 s, annealing at 56°C for 40 s and extension at 72°C for 50 s in a total volume of 15 ll.
For confirmation, the sense primer IDH1fc ACCAAA TGGCACCATACGA and antisense primer IDH1rc TTC ATACCTTGCTTAATGGGTGT generating a 254 bp fragment at the same PCR conditions were employed.
A fragment of 150 bp length spanning the sequence encoding the catalytic domain of IDH2 including codon 172 was amplified using 60 ng each of the sense primer IDH2f AGCCCATCATCTGCAAAAAC and the antisense primer IDH2r CTAGGCGAGGAGCTCCAGT. PCR using standard buffer conditions, 20 ng of DNA and GoTaq DNA Polymerase (Promega, Madison, USA) employed 35 cycles with denaturing at 95°C for 30 s, annealing at 58°C for 40 s and extension at 72°C for 50 s in a total volume of 15 ll.
For confirmation, the sense primer IDH2fc GCTGC AGTGGGACCACTATT and antisense primer IDH2rc TG TGGCCTTGTACTGCAGAG generating a 293 bp fragment at the same PCR conditions were employed.
Direct sequencing
Two microliters of the PCR amplification product were subjected to sequencing using the BigDye Terminator v3.1 Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Twenty-five cycles were performed employing 12 ng of the sense primers IDH1f CGGTCTTCAGAGA AGCCATT or IDH2f CTAGGCGAGGAGCTCCAGT, with denaturing at 95°C for 30 s, annealing at 56°C for 15 s and extension at 60°C for 240 s. In case of ambiguous readings, a second round of sequencing analysis was performed using the antisense primer IDH1rc TTCATACC TTGCTTAATGGGTGT or IDH2rc TTCATACCTTGC TTAATGGGTGT and the sequencing reaction conditions as described above. Sequences were determined using the semiautomated sequencer (ABI 3100 Genetic Analyzer, Applied Biosystems) and the Sequence Pilot version 3.1 software (JSI-Medisys, Kippenheim, Germany).
Statistics
The Fisher exact test was used to examine associations between nominal variables referring to absence or presence of genetic alterations. The relationship of IDH mutations with patient age was examined by Student's t test.
Results and discussion
We detected 716 IDH1 mutations and 31 IDH2 mutations in 1,010 patients with astrocytoma, oligodendroglioma or oligoastrocytoma of WHO grades II and III. Only codon 132 of IDH1 and codon 172 of IDH2 were affected by mutations. Previous studies did not detect IDH1 and IDH2 mutations in constitutional tissues [1, 8, 14, 17, 21] . Therefore, we did not analyze corresponding blood samples from the glioma patients included in this study. In the majority of the cases, mutations in codon 132 of IDH1 and codon 172 of IDH2 were obvious upon sequencing in forward direction. However, we encountered cases yielding only weak peaks in addition to the signal of the wild-type sequence. These cases suspected to carry a mutation were sequenced a second time in reverse direction. Reappearance of an additional signal at the site of suspect was then scored as positive for mutation. Based on direct sequencing, all mutations appeared to be heterozygous meaning that in each tumor with a mutation only one of the two gene copies of IDH1 or IDH2, respectively, was altered.
Type and frequency of IDH1 and IDH2 mutations
The predominant amino acid sequence alteration in IDH1 was R132H accounting for 92.7% of the detected mutations followed by R132C for 4.1%, R132S for 1.5%, R132G for 1.4% and R132L for 0.2% of all IDH1 mutations. Type and distribution of the mutations are given in Table 1 . We did not detect the R132V mutation reported and illustrated in our previous series [1] . The distribution of mutations in the present series matches well with those of other studies demonstrating the vast majority of IDH1 mutations being of the R132H type followed by R132C. The discrepancies in literature regarding the low frequencies of R132S, R132G and R132L may be due to differences in sample size and different types of tumors analyzed. In IDH2, the distribution of mutation types is less offcenter. R172K made up 65%, R172M amounted to 19% and the previously not described R172W to 16% of all IDH2 mutations. In contrast to the initial report on IDH2 mutations, we did not find the R172G exchange. While in several instances we detected a shallow G peak in nucleotide position 514, we interpreted this signal as artificial and caused by the flanking G nucleotides in positions 511, 512, 515 and 516 of the wild-type sequence of IDH2. An example for such a signal interpreted as sequencing artifact is shown in Fig. 1 .
The amino acid sequences of IDH1 and IDH2 at the sites of mutations are identical while the nucleotide sequences differ. It is noteworthy that the most frequent mutations in both IDH1 and IDH2 derive from a G to A transition in nucleotide position 395 of IDH1 and 515 of IDH2, respectively.
IDH1 and IDH2 mutations in astrocytoma, oligodendroglioma and oligoastrocytoma
We detected 716 IDH1 mutations in our series. Type and distribution of the mutations are given in Table 2 . A II carried mutations in 72.7% comparing well with frequencies of 74% [1] , 83% [21] , 88% [17] and 59% [8] reported in previous studies. IDH1 mutations in A III were observed in 64.0% comparable to 62% [1] , 69% [21] , 78% [17] and 52% [8] in earlier studies. The present frequency was 82% for O II comparing to 71% [1] , 82% [21] , 79% [17] and 68% [8] and 69.5% for O III comparing to 67% [1] , 86% [21] , 75% [17] and 60% [8] . OA II carried IDH1 mutations in 81.6 % comparing to 78% [1] , 100% [21] , 94% [17] and 50% [8] and OA III in 66.1% while the previous studies detected mutations in 78% [1] , 100% [21] , 71% [17] and 78% [8] . Thus, the frequencies in the present study are very similar to our previous series and well within the range of data published. This difference may in part be attributed to small numbers of particular subtypes of gliomas in the other studies; however, the use of different thresholds in scoring weaker signals as sufficient for a mutation may also play a role. Glioma tissues always contain a non-neoplastic cell compartment including vascular cells, reactive astrocytes, lymphocytes and microglial cells. In addition, the diffuse and infiltrative nature of glioma frequently results in a substantial fraction of residual brain in the tissue samples. Therefore, the mutant signal in gliomas heterozygous for mutations usually is less intense than the wild-type signal requiring a more or less arbitrary threshold level to separate between a signal indicating a mutation and a background peak.
Mutations in IDH2 mutations were much less common than those in IDH1. We found 31 IDH2 mutations in our series. A II and A III carried IDH2 mutation in 0.9% each while 4.7% of O II, 5.2% of O III, 1.3% of OA II and 6.2% of OA III had IDH2 mutations. Type and distribution of the mutations are given in Table 3 . A II carried IDH2 mutations in 0.9% which is considerably lower than the frequency of 7% previously observed [21] . Mutations in A III were observed in 0.9% and thus were also less frequent than the 4% reported in the preceding study [21] . The present frequency for O II and O III were 4.7 and 5.2% comparing well to 4 and 8% [21] . OA II and OA III carried mutations in 1.3 and 6.2% and have not previously been reported. Fig. 1 Example for a sequence with a small G signal at nucleotide position 394 of IDH2, which we did not score as evidence for a point mutation but rather considered as a sequencing artifact due to stuttering of polymerase induced by the flanking G signals Table 2 IDH1 mutations exhibited a non-random distribution among astrocytic and oligodendroglial tumors. In our previous study, we hinted at a trend for R132C mutations to favor astrocytomas. In the present series, a total of 29 R132C mutations were observed in 17 A II, 7 A III, 2 O III and 1 OA II and OA III each. This distribution favoring astrocytomas was highly significant (p \ 0.0001). The significance of the association of R132C with astrocytoma is further supported by a recent report. In a series of LiFraumeni patients with astrocytoma, only R132C mutations in IDH1 but not the more frequent R132H mutation were observed [18] . Because sporadic astrocytomas carry somatic mutations in the TP53 gene more frequently than oligodendrogliomas and oligoastrocytomas, and because Li-Fraumeni patients by definition have a germ line mutation in TP53, there seems to be an association of the IDH1 R132C mutation with mutations in TP53. Whether and how TP53 mutations favor the occurrence of IDH R132C mutations, as supported in the Li-Fraumeni setting, or whether IDH1 mutations favor subsequent TP53 mutations, as suggested by the significantly higher incidence of IDH1 mutations than the one of TP53 mutations in sporadic astrocytomas, remains yet unresolved. variability in the distinction of astrocytoma from oligoastrocytoma [3] . The WHO criteria do allow for a significant diagnostic overlap [12] and the problem is further aggravated by tissue sampling with usually only parts of the tumor tissue being available for histological analysis.
Another reason for this discrepancy may be our threshold in scoring mutations resulting in elimination of all R172G mutations reported previously. In our series, 22 of 31 IDH2 mutations occurred either in A III, O III or OA III. This represents a trend for an association with anaplastic tumors. While there is no doubt that IDH1 mutations occur early in tumor formation, because the majority of A II, O II and OA II already harbor this alteration, the time point of the occurrence of IDH2 mutations cannot definitely be set at a similar early point.
IDH1 and IDH2 are inversely associated
In the initial report on IDH2 mutations, only glioma samples not carrying IDH1 mutations were analyzed for IDH2 [21] . In order to analyze the potentially complementary effects of these mutations, we examined our entire series for both IDH1 and IDH2 mutations. We detected 712 tumors with an IDH1 mutation but wild type for IDH2, 27 tumors with IDH2 mutation but wild type for IDH1 and only 4 tumors, 1 A III, 1 O III and 2 OA III, characterized by both IDH1 and IDH2 mutations. Interestingly, the four tumors with mutations in both IDH1 and IDH2 were all anaplastic gliomas. This clearly is a non-random distribution (p \ 0.00001). Such partition indicates that either IDH1 or IDH2 mutations independently provide a growth advantage for mutant cells and that one of them is sufficient to mediate this advantage.
IDH1 and IDH2 mutations and age
In patients under the age of 18 years, IDH1 mutations were rare occurring in only 4 of 32 (12.5%) tumors and IDH2 mutations were absent. This finding suggests that pediatric astrocytomas, oligodendrogliomas and oligoastrocytomas genetically differ from their adult counterparts. The mean age of adult patients aged 18 or older with anaplastic nificant) . Patients carrying the most common R132H mutation averaged 42.9 years while patients with the R132C mutation were significantly younger averaging 34.9 years (p \ 0.01), those with the R132G mutation were 37.9 years old (not significant) and those carrying R132S averaged 36.2 years (p \ 0.01).
Conclusions
The present study provides a reliable basis for the frequencies and types of IDH1 codon 132 and IDH2 codon 172 mutations in diffusely infiltrating astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO grades II and III. The data confirm a high frequency of IDH1 mutation in these tumors, with 70.9% of all investigated tumors carrying an IDH1 codon 132 mutation, most commonly of the R132H type. In contrast, IDH2 mutations were restricted to 3.1% of the tumors. Our data confirm a mutually exclusive presence of either IDH1 or IDH2 mutation in gliomas. Furthermore, we show that the R132C IDH1 mutation is significantly associated with astrocytic histology, while IDH2 mutations are more common in oligodendroglial tumors as compared to astrocytomas. Further studies need to address the clinical impact of the individual IDH1 and IDH2 mutations with respect to their potential role as prognostic markers in patients with diffuse gliomas.
